NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $22.38M | $6.35M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $46.55M | $34.22M | $1.68M | $582.00K |
| Gross Profit | N/A | N/A | N/A | N/A | $-24.18M | $-27.87M | $-1.68M | $-582.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | -108.03% | -439.09% | 0.00% | 0.00% |
| Operating Expenses | $59.75M | $67.64M | $75.91M | $70.77M | $17.05M | $9.61M | $21.52M | $14.97M |
| Operating Income | $-59.75M | $-67.64M | $-75.91M | $-70.77M | $-41.23M | $-37.48M | $-23.20M | $-15.55M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Net Income | $-55.65M | $-62.72M | $-74.73M | $-69.39M | $-36.60M | $-33.74M | $-22.80M | $-15.47M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| EPS (Basic) | $-23.88 | $-27.04 | $-32.32 | $-30.15 | $-15.95 | $-25.79 | $-12.04 | $-8.17 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |